Terns Pharmaceuticals (TERN) shares jumped 53% following the release of highly promising Phase 2 trial data for its investigational therapy in treating relapsed or refractory acute myeloid leukemia (AML). The data demonstrated a significant overall response rate and durable remissions in key patient subgroups.
- Terns Pharmaceuticals (TERN) shares rose 53% following Phase 2 trial results.
- The trial included 62 patients with relapsed or refractory AML.
- Overall response rate reached 63%, with 32% achieving complete remission.
- Patients with IDH1/IDH2 mutations showed response rates above 75%.
- The therapy demonstrated durable remissions with a median duration of 11.2 months.
Terns Pharmaceuticals (TERN) experienced a sharp 53% increase in share price after announcing top-line results from a Phase 2 clinical trial evaluating its investigational agent in patients with relapsed or refractory acute myeloid leukemia (AML). The trial, which included 62 adult patients, reported an overall response rate (ORR) of 63%, with 32% achieving complete remission. Notably, patients with specific genetic mutations, including those with IDH1 and IDH2 mutations, showed even higher response rates exceeding 75%.